a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were allowed to be on monotherapy or dual therapy during the year before cohort ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

The current pathophysiology of COPD encompasses ... The advantage of this new model is that we now have the opportunity to intervene, and certain investigational medications are now being studied ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...